Detalhe da pesquisa
1.
Dysfunction of sinus macrophages in tumor-bearing host induces resistance to immunotherapy.
Cancer Sci
; 115(1): 59-69, 2024 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-37923388
2.
Blockade of PD-1/PD-L1 Pathway Enhances the Antigen-Presenting Capacity of Fibrocytes.
J Immunol
; 206(6): 1204-1214, 2021 03 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-33504617
3.
Identification of fibrocyte cluster in tumors reveals the role in antitumor immunity by PD-L1 blockade.
Cell Rep
; 42(3): 112162, 2023 03 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-36870329
4.
AntiVEGF antibody triggers the effect of antiPDL1 antibody in PDL1low and immune desertlike mouse tumors.
Oncol Rep
; 47(2)2022 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-34958105
5.
PD-L1 blockade exhibits anti-tumor effect on brain metastasis by activating CD8+ T cells in hematogenous metastasis model with lymphocyte infusion.
Clin Exp Metastasis
; 39(2): 335-344, 2022 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-34797455
6.
Effect of Bevacizumab on a Human Breast Cancer Model that Exhibited Palbociclib-resistance by RB Knockout.
Cancer Diagn Progn
; 2(5): 533-541, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-36060025
7.
Anti-VEGF Antibody Protects against Alveolar Exudate Leakage Caused by Vascular Hyperpermeability, Resulting in Mitigation of Pneumonitis Induced by Immunotherapy.
Mol Cancer Ther
; 20(12): 2519-2526, 2021 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-34552009
8.
Both T cell priming in lymph node and CXCR3-dependent migration are the key events for predicting the response of atezolizumab.
Sci Rep
; 11(1): 13912, 2021 07 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-34230534
9.
A defucosylated anti-CD317 antibody exhibited enhanced antibody-dependent cellular cytotoxicity against primary myeloma cells in the presence of effectors from patients.
Cancer Sci
; 101(10): 2227-33, 2010 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-20701608
10.
Generation of a humanized anti-glypican 3 antibody by CDR grafting and stability optimization.
Anticancer Drugs
; 21(10): 907-16, 2010 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-20847643
11.
Bevacizumab suppresses the growth of established non-small-cell lung cancer brain metastases in a hematogenous brain metastasis model.
Clin Exp Metastasis
; 37(1): 199-207, 2020 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-31768815
12.
Anti-glypican 3 antibodies cause ADCC against human hepatocellular carcinoma cells.
Biochem Biophys Res Commun
; 378(2): 279-84, 2009 Jan 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-19022220
13.
Sustained effect of continuous treatment with bevacizumab following bevacizumab in combination with chemotherapy in a human ovarian clear cell carcinoma xenograft model.
Oncol Rep
; 42(3): 1057-1065, 2019 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-31322247
14.
Cisplatin Augments Antitumor T-Cell Responses Leading to a Potent Therapeutic Effect in Combination With PD-L1 Blockade.
Anticancer Res
; 39(4): 1749-1760, 2019 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-30952714
15.
Topoisomerase I inhibitor, irinotecan, depletes regulatory T cells and up-regulates MHC class I and PD-L1 expression, resulting in a supra-additive antitumor effect when combined with anti-PD-L1 antibodies.
Oncotarget
; 9(59): 31411-31421, 2018 Jul 31.
Artigo
em Inglês
| MEDLINE | ID: mdl-30140379
16.
Importance of Bevacizumab Maintenance Following Combination Chemotherapy in Human Non-small Cell Lung Cancer Xenograft Models.
Anticancer Res
; 37(2): 623-629, 2017 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-28179309
17.
Bevacizumab counteracts VEGF-dependent resistance to erlotinib in an EGFR-mutated NSCLC xenograft model.
Int J Oncol
; 51(2): 425-434, 2017 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-28627678
18.
Continuous administration of bevacizumab plus capecitabine, even after acquired resistance to bevacizumab, restored anti-angiogenic and antitumor effect in a human colorectal cancer xenograft model.
Oncol Rep
; 36(2): 626-32, 2016 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-27350037
19.
Tocilizumab inhibits signal transduction mediated by both mIL-6R and sIL-6R, but not by the receptors of other members of IL-6 cytokine family.
Int Immunopharmacol
; 5(12): 1731-40, 2005 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-16102523
20.
Combining onartuzumab with erlotinib inhibits growth of non-small cell lung cancer with activating EGFR mutations and HGF overexpression.
Mol Cancer Ther
; 14(2): 533-41, 2015 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-25522765